Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.

Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1077-83. doi: 10.2215/CJN.04601007. Epub 2008 Apr 16.

2.

Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL.

Bradbury BD, Danese MD, Gleeson M, Critchlow CW.

Clin J Am Soc Nephrol. 2009 Mar;4(3):630-7. doi: 10.2215/CJN.03580708. Epub 2009 Mar 4.

3.

Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy.

Foley RN, Curtis BM, Parfrey PS.

Clin J Am Soc Nephrol. 2008 Nov;3(6):1669-75. doi: 10.2215/CJN.02100508. Epub 2008 Oct 15.

4.

A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease.

Spinowitz B, Germain M, Benz R, Wolfson M, McGowan T, Tang KL, Kamin M; Epoetin Alfa Extended Dosing Study Group.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1015-21. doi: 10.2215/CJN.05681207. Epub 2008 Apr 9.

5.

Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis.

McGowan T, Vaccaro NM, Beaver JS, Massarella J, Wolfson M.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1006-14. doi: 10.2215/CJN.05671207. Epub 2008 Apr 16.

6.

The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.

Ishigami J, Onishi T, Shikuma S, Akita W, Mori Y, Asai T, Kuwahara M, Sasaki S, Tsukamoto Y.

Clin Exp Nephrol. 2013 Feb;17(1):106-14. doi: 10.1007/s10157-012-0659-6. Epub 2012 Jul 3.

PMID:
22752396
7.

Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.

Vincent JL, Spapen HD, Creteur J, Piagnerelli M, Hubloue I, Diltoer M, Roman A, Stevens E, Vercammen E, Beaver JS.

Crit Care Med. 2006 Jun;34(6):1661-7.

PMID:
16607233
8.

Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.

Ogawa T, Shimizu H, Kyono A, Sato M, Yamashita T, Otsuka K, Nitta K.

Int Urol Nephrol. 2014 Jan;46(1):151-9. doi: 10.1007/s11255-013-0494-z. Epub 2013 Jun 27.

PMID:
23807369
9.

Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease.

Minutolo R, Chiodini P, Cianciaruso B, Pota A, Bellizzi V, Avino D, Mascia S, Laurino S, Bertino V, Conte G, De Nicola L.

Clin J Am Soc Nephrol. 2009 Mar;4(3):552-9. doi: 10.2215/CJN.04380808. Epub 2009 Mar 4.

10.

Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.

Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R; Epoetin Zeta Study Group.

Curr Med Res Opin. 2008 Mar;24(3):625-37. doi: 10.1185/030079908X273264. Erratum in: Curr Med Res Opin. 2008 Oct;24(10):3007. Curr Med Res Opin. 2008 Apr;24(4):1155.

PMID:
18208642
11.

Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.

Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U; PROTOS Study Investigators.

Clin J Am Soc Nephrol. 2007 Jul;2(4):637-46. Epub 2007 May 23.

12.

Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?

Pussell BA, Walker R; Australian Renal Anaemia Group.

Nephrology (Carlton). 2007 Apr;12(2):126-9.

PMID:
17371333
13.

A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia.

Pergola PE, Gartenberg G, Fu M, Wolfson M, Rao S, Bowers P.

Clin J Am Soc Nephrol. 2009 Nov;4(11):1731-40. doi: 10.2215/CJN.03470509. Epub 2009 Sep 17.

14.

Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.

McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, Singh AK, Szczech LA, Califf RM.

Am J Nephrol. 2013;37(6):549-58. doi: 10.1159/000351175. Epub 2013 May 25.

PMID:
23735819
15.

Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.

McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF Jr; End-Stage Renal Disease Core Indicators Work Group.

Am J Kidney Dis. 2001 May;37(5):E36.

PMID:
11325701
16.

Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?

Walker RG.

Clin J Am Soc Nephrol. 2008 Jul;3(4):935-7. doi: 10.2215/CJN.02300508. Epub 2008 Jun 25. No abstract available.

17.

Relationship between insulin resistance and erythropoietin responsiveness in hemodialysis patients.

Abe M, Okada K, Soma M, Matsumoto K.

Clin Nephrol. 2011 Jan;75(1):49-58.

PMID:
21176750
18.

A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia.

Pergola PE, Gartenberg G, Fu M, Sun S, Wolfson M, Bowers P.

Clin J Am Soc Nephrol. 2010 Apr;5(4):598-606. doi: 10.2215/CJN.06770909. Epub 2010 Feb 25.

19.

Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis.

Goodkin DA, Gimenez LF, Graber SE, Van Stone JC, Egrie JC, Okamoto DM.

Clin Nephrol. 1999 Jun;51(6):367-72.

PMID:
10404697
20.

Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.

Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A; Epoetin Zeta Study Group.

Adv Ther. 2010 Feb;27(2):105-17. doi: 10.1007/s12325-010-0012-y. Epub 2010 Mar 30.

PMID:
20369312

Supplemental Content

Support Center